Glenn J. Hanna
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Glenn J. Hanna as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:31 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT05553782 · Drug Screening Using Novel IMD in Salivary and Head and Neck CancersBrigham and Women's Hospital · recruiting · Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck · principal investigator
- Ph2NCT04832438 · 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland CarcinomaActuate Therapeutics Inc. · withdrawn · Salivary Gland Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Cancer
- Ph2NCT04620187 · Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasDana-Farber Cancer Institute · recruiting · Salivary Gland Cancer, HER2 Gene Mutation
- Ph1/Ph2NCT04339062 · Cemiplimab in AlloSCT/SOT Recipients With CSCCDana-Farber Cancer Institute · completed · Cutaneous Squamous Cell Carcinoma, Advanced Cancer
- Ph2NCT03999684 · A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic CarcinomaDana-Farber Cancer Institute · completed · Adenoid Cystic Carcinoma · principal investigator
- Ph2NCT03341936 · Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNDana-Farber Cancer Institute · active not recruiting · Squamous Cell Carcinoma of the Head and Neck · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:31 UTC. The ranking covers the 200 most relevant of 70 PubMed records, and a shared surname and initials can bring in a namesake. All 70 on PubMed
- Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.Clin Cancer Res · 2020346 citationsRCR 13.8
- Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.JAMA Oncol · 2020315 citationsRCR 12.4
- ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.PLoS Pathog · 2007289 citationsRCR 6.3
- 151 citationsRCR 7.5
- 134 citationsRCR 6.1
- "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.HIV Clin Trials · 2008128 citationsRCR 4.2
- The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.J Acquir Immune Defic Syndr · 2007116 citationsRCR 3.9
- First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.J Immunother Cancer · 2021112 citationsRCR 5.7
- Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.J Infect Dis · 2000103 citationsRCR 2.6
- A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.J Infect Dis · 2008102 citationsRCR 2.9